Fennec Pharmaceuticals Inc. (FENC) has a negative trailing P/E of -19.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 34.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -5.17%, forward earnings yield 2.93%. PEG 0.37 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -54.5 | -0.21 | 42.61 | 0.00 | - |
| 2017 | -21.3 | -0.19 | 5.61 | 0.00 | - |
| 2018 | -12.2 | -1.15 | 5.67 | 0.00 | - |
| 2019 | -9.9 | -0.47 | 10.87 | 0.00 | - |
| 2020 | -9.8 | -0.47 | 6.07 | 1,038.79 | - |
| 2021 | -6.7 | 0.56 | 7.26 | 0.00 | - |
| 2022 | -11.1 | -0.27 | -98.19 | 171.11 | - |
| 2023 | -18.6 | 0.50 | -25.65 | 14.03 | - |
| 2024 | -395.6 | 4.06 | -29.38 | 3.63 | - |
| 2025 | -21.4 | -0.01 | 6.28 | 4.84 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.22 | $0.00 | $-2.79M | - |
| 2017 | $-0.47 | $0.00 | $-7.05M | - |
| 2018 | $-0.52 | $0.00 | $-9.89M | - |
| 2019 | $-0.63 | $0.00 | $-12.46M | - |
| 2020 | $-0.76 | $170K | $-17.92M | -10542.4% |
| 2021 | $-0.67 | $0.00 | $-17.46M | - |
| 2022 | $-0.95 | $1.54M | $-24.84M | -1618.2% |
| 2023 | $-0.60 | $21.25M | $-16.05M | -75.5% |
| 2024 | $-0.02 | $47.54M | $-436K | -0.9% |
| 2025 | $-0.36 | $45.42M | $-10.27M | -22.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.23 | $0.13 – $0.30 | $72.86M | $68.55M – $74.95M | 5 |
| 2027 | $0.84 | $0.72 – $0.93 | $103.06M | $99.03M – $110.35M | 5 |
| 2028 | $1.43 | $0.94 – $1.76 | $133.78M | $130.88M – $136.68M | 3 |
| 2029 | $2.47 | $2.09 – $2.72 | $188.67M | $166.26M – $203.41M | 1 |
| 2030 | $2.55 | $2.15 – $2.80 | $202.88M | $178.78M – $218.73M | 1 |
